Evidence map›Paper›PMID 36687267›Full record

ArticleJACC. Basic to translational science2022

Novel GSK-3β Inhibitor Neopetroside A Protects Against Murine Myocardial Ischemia/Reperfusion Injury.

Hyoung Kyu Kim, Min Kim, Jubert C Marquez, Seung Hun Jeong, Tae Hee Ko, Yeon Hee Noh, Pham Trong Kha, Ha Min Choi, Dong Hyun Kim, Jong Tae Kim and 10 more

Open access · goldAbstract read
In one paragraph

Article in JACC. Basic to translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Histone Deacetylase 6 Controls Atrial Fibrosis and Remodeling in Postinfarction Mice Through the Modulation of Wnt3a/GSK-3β Signaling.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Review
  4. Article
  5. Article
  6. Mitochondrial Kinase Signaling for Cardioprotection.International journal of molecular sciences · 2024
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 2 countries.

Hyoung Kyu KimCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Min KimCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Jubert C MarquezCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Seung Hun JeongCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Tae Hee KoCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Yeon Hee NohCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Pham Trong KhaCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Ha Min ChoiCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Dong Hyun KimDepartment of Pharmacology and Pharmaco-Genomics Research Center, College of Medicine, Inje University, Busan, South Korea.
Jong Tae KimPaik Institute for Clinical Research, Inje University College of Medicine, Busan, South Korea.
Young Il YangPaik Institute for Clinical Research, Inje University College of Medicine, Busan, South Korea.
Kyung Soo KoCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Byoung Doo RheeCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Larisa K ShubinaG.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far-Eastern Branch of the Russian Academy of Science, Vladivostok, Russia.
Tatyana N MakarievaG.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far-Eastern Branch of the Russian Academy of Science, Vladivostok, Russia.
Dmitry Y YashunskyLaboratory of Glycoconjugate Chemistry, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Alexey G GerbstLaboratory of Glycoconjugate Chemistry, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Nikolay E NifantievLaboratory of Glycoconjugate Chemistry, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia.
Valentin A StonikG.B. Elyakov Pacific Institute of Bioorganic Chemistry, Far-Eastern Branch of the Russian Academy of Science, Vladivostok, Russia.
Jin HanCardiovascular and Metabolic Disease Center, Inje University, Busan, South Korea.
Inje University · KRN.D. Zelinsky Institute of Organic Chemistry · RUPacific Institute of Bioorganic Chemistry. GB Elyakova Far Eastern Branch of the Russian Academy of Sciences · RUInje University Busan Paik Hospital · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recent trends suggest novel natural compounds as promising treatments for cardiovascular disease. The authors examined how neopetroside A, a natural pyridine nucleoside containing an α-glycoside bond, regulates mitochondrial metabolism and heart function and investigated its cardioprotective role against ischemia/reperfusion injury. Neopetroside A treatment maintained cardiac hemodynamic status and mitochondrial respiration capacity and significantly prevented cardiac fibrosis in murine models. These effects can be attributed to preserved cellular and mitochondrial function caused by the inhibition of glycogen synthase kinase-3 beta, which regulates the ratio of nicotinamide adenine dinucleotide to nicotinamide adenine dinucleotide, reduced, through activation of the nuclear factor erythroid 2-related factor 2/NAD(P)H quinone oxidoreductase 1 axis in a phosphorylation-independent manner.

Indexed as

ATP, adenosine triphosphateGSK-3, glycogen synthase kinase–3GSK-3β inhibitionI/R, ischemia/reperfusionischemia/reperfusion injurymarine pyridine α-nucleosideMI, myocardial infarctionmitochondriamPTP, mitochondrial permeability transition poremTOR, mammalian target of rapamycinNADH, nicotinamide adenine dinucleotide, reducedNAD+, nicotinamide adenine dinucleotideNPS ANPS A, neopetroside ANqo1, NAD(P)H:quinone oxidoreductase 1Nrf2, nuclear factor erythroid 2–related factor 2OCR, oxygen consumption rate

Identifiers

PMID36687267
PMCPMC9849271
OpenAlexW4297513751

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.